Total Payments
$9,292
2024 Payments
$1,774
Companies
23
Transactions
88
Payment Breakdown by Category
Research$8,154 (87.8%)
Food & Beverage$1,138 (12.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,154 | 16 | 87.8% |
| Food and Beverage | $1,138 | 72 | 12.2% |
Payments by Type
Research
$8,154
16 transactions
General
$1,138
72 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $6,653 | 21 | $0 (2023) |
| SANOFI PASTEUR INC. | $1,752 | 15 | $0 (2024) |
| Neos Therapeutics, LP | $208.70 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $139.87 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $78.96 | 1 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $70.08 | 5 | $0 (2021) |
| kaleo, Inc. | $53.36 | 3 | $0 (2023) |
| SANOFI US SERVICES INC. | $33.00 | 1 | $0 (2024) |
| Shire North American Group Inc | $30.82 | 2 | $0 (2019) |
| Cranial Technologies, Inc | $30.48 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,774 | 15 | SANOFI PASTEUR INC. ($1,713) |
| 2023 | $6,559 | 11 | PFIZER INC. ($6,408) |
| 2022 | $91.30 | 5 | Merck Sharp & Dohme LLC ($60.58) |
| 2021 | $70.54 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($41.84) |
| 2020 | $155.03 | 11 | PFIZER INC. ($54.30) |
| 2019 | $134.03 | 9 | PFIZER INC. ($86.88) |
| 2018 | $235.04 | 13 | Novartis Pharmaceuticals Corporation ($78.96) |
| 2017 | $272.78 | 19 | Neos Therapeutics, LP ($157.67) |
All Payment Transactions
88 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $33.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/16/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: ADHD | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $185.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $487.63 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $163.69 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 01/03/2024 | Neos Therapeutics, LP | Adzenys XR-ODT (Drug) | Food and Beverage | Cash or cash equivalent | $13.91 | General |
| Category: ADHD | ||||||
| 11/28/2023 | ALK-Abello, Inc | Ragwitek (Drug), Grastek, Odactra | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Allergy and Immunology | ||||||
| 11/14/2023 | Seqirus USA Inc | FLUCELVAX QUADRIVALENT (Biological) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Vaccines | ||||||
| 10/19/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,178.00 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/18/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 09/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,013.65 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/19/2023 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Allergy | ||||||
| 08/15/2023 | Merck Sharp & Dohme LLC | VAXELIS (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: VACCINE | ||||||
| 04/13/2023 | Merck Sharp & Dohme LLC | PROQUAD (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: VACCINE | ||||||
| 04/06/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,215.90 | Research |
| Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 03/02/2023 | Cranial Technologies, Inc | Doc Band (Device) | Food and Beverage | Cash or cash equivalent | $16.47 | General |
| Category: Cranial Orthotic | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $6,408 | 3 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $1,713 | 12 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI US SERVICES INC. | $33.00 | 1 |
About Dr. Edward Henderson, DO
Dr. Edward Henderson, DO is a Pediatrics healthcare provider based in Midlothian, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1821380189.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Henderson, DO has received a total of $9,292 in payments from pharmaceutical and medical device companies, with $1,774 received in 2024. These payments were reported across 88 transactions from 23 companies. The most common payment nature is "" ($8,154).
Ad
Practice Information
- Specialty Pediatrics
- Location Midlothian, VA
- Active Since 05/05/2011
- Last Updated 01/19/2021
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1821380189
Products in Payments
- NURTEC ODT (Drug) $6,408
- EUCRISA (Drug) $245.75
- Adzenys XR-ODT (Drug) $208.70
- VYVANSE (Drug) $84.37
- XOLAIR (Biological) $78.96
- GARDASIL 9 (Biological) $60.58
- AUVI-Q (Drug) $53.36
- Crysvita (Drug) $34.86
- Doc Band (Device) $30.48
- VAXELIS (Biological) $24.73
- SYNAGIS (Biological) $24.48
- Xofluza (Drug) $23.87
- BEXSERO (Biological) $23.19
- Ragwitek (Drug) $22.74
- PROQUAD (Biological) $19.27
- GARDASIL9 (Biological) $17.88
- ROTATEQ (Biological) $17.41
- SYNAGIS (Drug) $16.98
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $16.33
- FLUCELVAX QUADRIVALENT (Biological) $16.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Midlothian
Dr. Patricia Mulreany, M.d, M.D
Pediatrics — Payments: $880,984
Pediatrics $880,984
Dr. Judith Grossberg, Md, MD
Pediatrics — Payments: $170,697
Pediatrics $170,697
Dr. Martha Saunders, Md, MD
Pediatrics — Payments: $169,110
Pediatrics $169,110
Dr. Elizabeth Cullen, Md, MD
Pediatrics — Payments: $168,389
Pediatrics $168,389
Margaret Sigman
Pediatrics — Payments: $17,303
Pediatrics $17,303
Kathy Bryant, Cpnp, Fnp-Bc, CPNP, FNP-BC
Pediatrics — Payments: $5,668
Pediatrics $5,668